Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

U.S. President Donald Trump listens to remarks during a swearing-in ceremony for Administrator of the Centers for Medicare ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

Thousands of Rhode Island seniors and disabled residents no longer covered for non-emergency visits at four local hospitals ...

Medicare is on shaky ground in the current policy environment, making it difficult to sustain its accomplishments, much less ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The federal government's Medicare program and older adults together spend $4.4 billion a year on care that has low clinical ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment ...